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Pulmonary carcinomas induced by iV-nitrosobis(2-oxopropyl)
amine (BOP) in WBN/Kob rats were screened for point
mutations in the K-ras protooncogene. Exons 1 and 2 were
polymerase chain reaction amplified from paraffin-embedded
sections, followed by direct DNA sequencing. G — A transi-
tion mutations in the second base of codon 12 of the K-ras
gene were found in 6/24 (25%) rat lung tumors induced by
BOP. The incidence of point mutations was significantly
higher (P < 0.005) in squamous cell carcinomas (5/7; 71%)
than in adenocarcinomas (1/17; 6%), suggesting that the
mutational activation of K-ras is associated with a differential
growth advantage in these two histologically distinct types of
lung tumors in rats. No mutations were found in codons 13,
61 or adjacent regions of these codons.
Altered expression or mutational activation of the ras
protooncogene family are the most common genetic alterations
in human and animal neoplasms (1 — 5). Activation of ras genes
generally occurs by the introduction of a point mutation in codons
12, 13 or 61 (1-5) . The members of the ras family of
protooncogenes, i.e. H-ras, K-ras and N-ras, appear to be
activated with a certain organ preference. In the lung, mutational
activation of the K-ras protooncogene seems to prevail and has
been identified as one of the major steps leading to malignant
transformation both in humans and rodents (1,2,6-9).
There is increasing evidence that several factors, i.e. causative
agents, cell types and host factors, modify the mutational
activation of the K-ras gene in lung carcinogenesis. In human
lung cancer, K-ras mutations, mostly G — T transversions in
codon 12, have been detected in ~ 30% of adenocarcinomas from
smokers (8,9), but they were rarely or never found in
adenocarcinomas from non-smokers (9) or in the other histologic
types of lung cancer including small cell carcinomas, large cell
carcinomas and squamous cell carcinomas (8,10). In the
development of murine lung tumors, the incidence of K-ras
mutations, the ras codon affected (12, 13 or 61), and mutational
pattern largely depend on the type of chemical carcinogen by
which the respective neoplasm was induced (11-18). The
incidence and pattern of K-ras mutations are also influenced by
•Abbreviations: BOP, W-nitrosobis(2-oxopropyl)amine; PCR, polymerase chain
reaction; NNK, 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone.
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host factors, e.g. genetic susceptibility (19,20). Here we present
evidence that in nitrosamine-induced lung tumors of the rat, the
involvement of K-ras mutations depends on the histological tumor
type.
Forty male 5 week old WBN/Kob rats (Japan SLC, Inc.,
Shizuoka, Japan) were treated with JV-nitrosobis(2-oxopropyl)
amine (BOP*) by s.c. injection of 20 mg BOP/kg body wt once
a day for S days. Rats were killed after 52 weeks and lung tumors
were fixed with buffered formalin, and embedded in paraffin.
These lung tumors were histologically classified into two types,
adenocarcinomas and squamous cell carcinomas. Adenocar-
cinomas were alveolar tumors with glandular or papillary
structures. Squamous cell carcinomas were well differentiated
and keratin pearl formation was prominent in most cases (21).
In the present study, 17 adenocarcinomas from eight rats and
seven squamous cell carcinomas from five rats were analyzed
for K-ras mutations as shown in Table I.
DNA from lung tumors was extracted from paraffin-embedded
sections as described previously (22). A mixture of DNA solution
(5 ill), 12.5 pmol of each primer, 200 jtM dNTPs, 10 mM Tris
(pH 8.8), 50 mM KC1, 1 mM MgCl2, and 2.5 U Taq poly-
merase in a total volume of 50 jtl was subjected to 40 amplifica-
tion cycles using a Perkin-Elmer Cetus thermal cycler (DNA
denaturation at 94°C for 1 min, primer annealing at 50°C for
1 min and extension at 72°C for 1.5 min). Sequences of primers
for amplification of the K-ras gene were 5'-GCCTGCTGAAA-
ATGACTGAG and 5'-CTCTATCGTAGGATCATATT for
exon 1 and 5'-GACTCCTACAGGAAACAAGT and 5'-AGA-
AAGCCCTCCCCAGTTCT for exon 2. Negative control
samples for polymerase chain reaction (PCR) without DNA
showed no amplification in each reaction. After amplification,
40 nl of the PCR reaction was electrophoresed on a 6%
polyacrylamide gel. The amplified bands were cut out, eluted
in 0.5 M ammonium acetate and 1 mM EDTA at 37°C overnight
and precipitated with ethanol. Dried DNA was resuspended in
10 /il of TE buffer.
Sanger dideoxynucleotide sequencing was performed using
[a-32P]dATP and sequencing primer (5'-CATCCACAAAGT-
GATTCTG for exon 1 and 5'-GTAATTGATGGAGAAACC-
TG for exon 2). The template—primer mixture (4 pi DNA
solution and 10 pmol primer) in 10 pil reaction buffer (10%
DMSO, 20 mM Tris-HCl, pH 7.5, 10 mM MgCl2 and 25 mM
NaCl) was heated at 95°C for 5 min and immediately placed in
liquid nitrogen. After adding 0.1 M dithiothreitol, 0.5 pCi
[a-32P]-dATP and 2 U of Sequenase version 2.0 CUSB),
samples were divided into four wells containing each termination
mixture and incubated at 37°C for 10 min. Samples were mixed
with 4 pi stop solution, heated at 80°C for 2 min and immediately
loaded onto a 6% polyacrylamide/7 urea gel. Gels were dried
and autoradiographed for 1—5 days. Samples that showed
mutations were repeatedly confirmed by independent PCR and
sequencing. Normal rat liver DNA was amplified and sequenced
in each reaction.
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Table I. Mutations in codon 12 of the K-ras gene in lung tumors induced
by BOP in WBN/Kob rats
Rat Tumor Histology Mutation in K-ras
codon 12 (GGT
- GAT)
SP5
SP6
SP7
SP9
SP11
SP13
SP14
SP16
SP22
SP28
SP31
SP39
a
b
a
b
c
a
b
c
a
a
b
c
A
V
f
a
a
a
a
b
a
a
a
b
adenocarcinoma
adenocarcinoma
adenocarcinoma
adenocarcinoma
adenocarcinoma
adenocarcinoma
squamous cell carcinoma
squamous cell carcinoma
adenocarcinoma
adenocarcinoma
adenocarcinoma
adenocarcinoma
adenocarcinoma
adenocarcinoma
adenocarcinoma
adenocarcinoma
squamous cell carcinoma
squamous cell carcinoma
squamous cell carcinoma
squamous cell carcinoma
squamous cell carcinoma
adenocarcinoma
adenocarcinoma
adenocarcinoma
A C G T A C G T A C G T
\
Codon 12 IG/A
IT
IGG
7
Squamous cell Squamous cell Normal liver
carcinoma carcinoma
Fig. 1. DNA sequencing autoradiographs of the K-ras protooncogene in rat
lung tumors induced by BOP. The additional bands A are shown at the
second base (G) of codon 12 of the K-ras gene in a squamous cell
carcinoma in rat no. SP7 (left) and a squamous cell carcinoma in rat no.
SP22 (middle). Normal rat liver DNA shows the wild-type sequence
(right).
Transition mutations in the second base of codon 12 of the
K-ras gene (GGT — GAT) were identified in 6/24 (25%) of rat
lung tumors induced by BOP (Table I). In all cases, wild-type
base was detected together with mutated base. Typical DNA
sequencing autoradiographs are shown in Figure 1. The incidence
of point mutations was significantly higher (P < 0.005) in
squamous cell carcinomas (5/7; 71 %) than in adenocarcinomas
(1/17; 6%). This tendency is exemplified by rat SP7 in which
two pulmonary squamous cell carcinomas contained K-ras
mutations, whereas the simultaneously induced adenocarcinoma
did not (Table I). No mutation was observed in codons 13 or
61, or in the surrounding regions of these codons.
While murine lung tumors are almost exclusively adenomas
or adenocarcinomas, rats develop squamous cell carcinomas as
well as adenocarcinomas, though the former are usually less
frequent. The present study was carried out on tumors that
developed in inbred Wistar rats treated with BOP (21). BOP is
a Af-nitroso compound which is enzymically converted to a
methylating agent that reacts with various cell constituents,
including nucleic acids. Among the promutagenic DNA bases
produced by this class of methylating iV-nitroso compounds,
O^methyldeoxyguanosine causes G — A transition mutations
during DNA replication. This type of mutation was first shown
to be present in rat mammary tumors induced by NMU which
consistently contain a G — A transition mutation in codon 12
of the H-ras gene (23). Similarly, it has been reported that
pancreatic duct carcinomas in hamsters induced by BOP contain
a high incidence of G — A mutations in the second base of codon
12 of the K-ras gene (24—26). The presence of the same mutation
in rat lung tumors induced by BOP (Table I) suggests that these
mutations, too, are directly produced by this carcinogen, most
likely through the formation of C^-methyldeoxyguanosine.
The present study showed a mutational activation of the K-ras
gene in >70% of BOP-induced squamous cell carcinomas,
whereas adenocarcinomas induced in rats by the same carcinogen
in the same experiment contained K-ras mutations 10 times less
frequently (6%). This suggests that in the lung of this rat strain
K-ras mutations in codon 12 confer a cell-type-specific growth
advantage. K-ras mutations have been also observed in 3/4 (73 %)
pulmonary squamous cell carcinomas induced by tetranitro-
methane (27) and in 11/33 (33%) of these tumors induced by
plutonium-239 (28). At high doses, the tobacco-specific nitros-
amine 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone (NNK)
induces squamous cell carcinomas (29) in rat lung, but there are
no reports on the presence of ras mutations in this histological
subtype.
In rat pulmonary adenomas and adenocarcinomas, the
involvement of K-rar mutations appears to be controversial.
Stowers et al. (27) reported that 9/12 (75%) adenocarcinomas
induced by tetranitromethane in F344 rats contained point
mutations in the second base of codon 12 of the K-ras gene.
Similarly, adenomas and adenocarcinomas induced by
plutonium-239 in F344 rats contained mutations in the first or
second base of codon 12 of the K-ras gene at an incidence of
46% (28), whereas Belinsky et al. (30,31) reported the complete
absence of K-ras mutations in lung adenomas and
adenocarcinomas induced by NNK in F344 rats. The biological
basis of this discrepancy is not fully elucidated. It should,
however, be noted that BOP and NNK require cytochrome
P450-mediated bioactivation, which often occurs in a cell-specific
mode (29—31) and that both carcinogens exert their adverse
effects through the formation of methyl cations as the ultimate
carcinogen. Tetranitromethane utilizes different enzymatic
pathways and its ultimate reactive form is not known. Plutonium
is assumed to act randomly without preference for specific cell
types and produces DNA damage different from that by
methylating agents. Belinsky et al. (29-31) reported that after
treatment with NNK, the level of C^-methylguanine in
bronchiolar Clara cells of the rat lung was up to 30-fold higher
than that in alveolar type II cells. Although the level of
C^-methylguanine in Clara cell DNAs and the tumor incidence
correlated well in a dose—response manner, the neoplasms
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induced by NNK in rat lung may actually be derived from
alveolar type II cells (29-31). The infrequent mutational
activation of the K-ras gene in NNK- and BOP-induced
adenocarcinomas may indicate that these two JV-nitroso
compounds share the same target (type II cells) for malignant
transformation and that in this cell type, the acquisition of K-ras
mutations does not confer a significant growth advantage.
Since BOP induces both adenocarcinomas and squamous cell
carcinomas in rats, this experimental model may prove useful
for the study of molecular mechanisms involved in the
development of these two different histologic types of lung
tumors.
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